Related Experiment Video
Updated: May 8, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
New combinations and immunotherapies for melanoma: latest evidence and clinical utility
Alexander M Menzies1, Georgina V Long
1Melanoma Institute Australia, University of Sydney, Sydney, Australia.
Abstract:
Until recently there was no effective systemic therapy for metastatic melanoma. Increased understanding of tumor biology and immune regulation has led to the development of drugs targeting the mitogen-activated protein kinase (MAPK) pathway (BRAF inhibitors and MEK inhibitors) and T-cell regulation (CTLA4 antibodies). These drugs are the new standard of care, however barriers to better patient outcomes include limited responses and significant toxicities (CTLA4 antibodies) and lack of durability in the majority of cases (BRAF and MEK inhibitors). This review discusses the next stages of development of treatments in melanoma, including immune checkpoint blocking drugs targeting the PD-1/PD-L1 axis, and the use of BRAF and MEK inhibitors in combination. Both approaches lead to a higher proportion of durable responses coupled with less toxicity. In an effort to improve outcomes even further, clinical trials of combinations of MAPK inhibitors, immunotherapies and other signal pathway inhibitors are underway. Adjuvant studies of many of these drugs have commenced, with the hope of also improving outcomes in patients with early-stage melanoma.
Insights
New melanoma treatments, including targeted therapies and immunotherapies, offer improved durable responses and reduced toxicity. Further research combines these approaches for even better patient outcomes in advanced and early-stage melanoma.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Metastatic melanoma previously lacked effective systemic therapies.
- Advances in tumor biology and immune regulation have introduced targeted drugs.
- Current treatments include BRAF/MEK inhibitors and CTLA4 antibodies, but face limitations like response durability and toxicity.
Purpose of the Study:
- To review the next stages of melanoma treatment development.
- To discuss emerging therapies and combination strategies.
- To explore potential improvements for early-stage melanoma patients.
Main Methods:
- Review of current and emerging treatment modalities for metastatic melanoma.
- Discussion of immune checkpoint inhibitors targeting the PD-1/PD-L1 axis.
- Analysis of combination therapies involving MAPK inhibitors and immunotherapies.
Main Results:
- Combination of BRAF/MEK inhibitors and immune checkpoint blockers show promise for durable responses with less toxicity.
- Ongoing clinical trials are investigating combinations of MAPK inhibitors, immunotherapies, and other signal pathway inhibitors.
- Adjuvant studies are exploring the efficacy of these drugs in early-stage melanoma.
Conclusions:
- Next-generation melanoma treatments focus on combination therapies for enhanced efficacy and safety.
- Targeting the PD-1/PD-L1 axis and combining MAPK inhibitors represent significant advancements.
- Adjuvant therapy holds potential for improving outcomes in early-stage melanoma.
Related Concept Videos
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...